Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: Results of a five-year brain MRI study

Journal of the Neurological Sciences

Volumn 312, Issue 1-2, 2012, Pages 7-12

  Khan, Omar ^a   Bao, Fen ^a   Shah, Megha ^a   Caon, Christina ^a   Tselis, Alexandros ^a   Bailey, Ronald ^b   Silverman, Bruce ^c   Zak, Imad ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Riverside Medical Center   (United States)

^c Providence Hospital   (United States)

Author keywords

Brain atrophy; Disease modifying therapies; Glatiramer acetate; Interferon beta; Neurodegeneration; Relapsing remitting MS

Indexed keywords

BETA INTERFERON; GLATIRAMER; METHYLPREDNISOLONE; PREDNISONE;

ARTICLE; BRAIN ATROPHY; BRAIN RADIOGRAPHY; BRAIN SIZE; CONTROLLED STUDY; DISEASE DURATION; DISEASE MODIFYING THERAPY; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; RELAPSING REMITTING MULTIPLE SCLEROSIS; THERAPY; TREATMENT RESPONSE;

ADULT; BRAIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE DEGENERATION; PEPTIDES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84155164255     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.08.034     Document Type: Article

References (35)

1. N.C. Fox, R. Jenkins, S.M. Leary, V.L. Stevenson, N.A. Losseff, and W.R. Crum Progressive cerebral atrophy in MS Neurology 54 2000 807 812
2. J.H. van Waesberghe, W. Kamphorst, C.J. De Groot, M.A. van Walderveen, J.A. Castelijns, and R. Ravid Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability Ann Neurol 46 1999 747 754 (Pubitemid 29518136)
3. H. Vrenken, J.J. Geurts, D.L. Knol, L.N. van Dijk, V. Dattola, and B. Jasperse Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter Radiology 240 2006 811 820 (Pubitemid 44267339)
4. U. Bonati, L.K. Fisniku, D.R. Altmann, M.C. Yiannakas, J. Furby, and A.J. Thompson Cervical cord and brain grey matter atrophy independently associate with long-term MS disability J Neurol Neurosurg Psychiatry 82 2011 471 472
5. C. Lukas, A. Minneboo, V. de Groot, B. Moraal, D.L. Knol, and C.H. Polman Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis J Neurol Neurosurg Psychiatry 81 2010 1351 1356
6. M. Di Filippo, V.M. Anderson, D.R. Altmann, J.K. Swanton, G.T. Plant, and A.J. Thompson Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes J Neurol Neurosurg Psychiatry 81 2010 204 208
7. M. Rovaris, G. Comi, M.A. Rocca, J.S. Wolinsky, and M. Filippi Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications Brain 124 2001 1803 1812 (Pubitemid 32845441)
8. M.P. Sormani, M. Rovaris, P. Valsasina, J.S. Wolinsky, G. Comi, and M. Filippi Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis Neurology 62 2004 1432 1434 (Pubitemid 38526067)
9. J.S. Wolinsky, P.A. Narayana, and K.P. Johnson United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates: multiple sclerosis study group and the MRI analysis center Mult Scler 7 2001 33 41 (Pubitemid 32396577)
10. C. Gasperini, A. Paolillo, E. Giugni, S. Galgani, F. Bagnato, and C. Mainero MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a Mult Scler 8 2002 119 123 (Pubitemid 34256748)
11. C.K. Jones, A. Riddehough, D.K.B. Li, G. Zhao, and D.W. Paty MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial Neurology 56 Suppl. 3 2001 A379
12. R.A. Rudick, E. Fisher, J.C. Lee, J. Simon, and L. Jacobs Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group Neurology 53 1999 1698 1704 (Pubitemid 29530342)
13. R. Zivadinov, A.T. Reder, M. Filippi, A. Minagar, O. Stuve, and H. Lassmann Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis Neurology 71 2008 136 144
14. R.A. Bermel, and R. Bakshi The measurement and clinical relevance of brain atrophy in multiple sclerosis Lancet Neurol 5 2006 158 170 (Pubitemid 43107851)
15. A.B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, and H.F. McFarland Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b Neurology 59 2002 688 694
16. S.M. Smith, Y. Zhang, M. Jenkinson, J. Chen, P.M. Matthews, and A. Federico Accurate, robust, and automated longitudinal and cross-sectional brain change analysis Neuroimage 17 2002 479 489
17. P. Tappenden, C. McCabe, J. Chilcott, E. Simpson, R. Nixon, and J. Madan Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population Value Health 12 2009 657 665
18. E. Fisher, R.A. Rudick, J.H. Simon, G. Cutter, M. Baier, and J.-C. Lee Eight-year follow-up study of brain atrophy in patients with MS Neurology 59 2002 1412 1420 (Pubitemid 35285996)
19. D.H. Miller, D. Soon, K.T. Fernando, D.G. MacManus, G.J. Barker, and T.A. Yousry MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS Neurology 68 2007 1390 1401 (Pubitemid 46659091)
20. M.K. Racke, and A.E. Lovett-Racke Glatiramer acetate treatment of multiple sclerosis: an immunological perspective J Immunol 186 2011 1887 1890
21. 1H MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term H MRS monitoring in multiple sclerosis J Neuroimaging 18 2008 314 319
22. M. Filippi, M. Rovaris, M.A. Rocca, M.P. Sormani, J.S. Wolinsky, and G. Comi Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes" Neurology 57 2001 731 733 (Pubitemid 32783013)
23. C.C. Ford, K.P. Johnson, R.P. Lisak, H.S. Panitch, G. Shifronis, and J.S. Wolinsky A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Mult Scler 12 2006 309 320 (Pubitemid 43827186)
24. G. Comi, M. Filippi, and J.S. Wolinsky European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group Ann Neurol 49 2001 290 297 (Pubitemid 32202781)
25. M. Hardmeier, S. Wagenpfeil, P. Freitag, E. Fisher, R.A. Rudick, and M. Kooijmans Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a Neurology 64 2005 236 240
26. M. Filippi, M. Rovaris, M. Inglese, F. Barkhof, N. De Stefano, and S. Smith Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial Lancet 364 2004 1489 1496 (Pubitemid 39410414)
27. L. Kappos, A. Traboulsee, C. Constantinescu, J.P. Erälinna, F. Forrestal, and P. Jongen Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS Neurology 67 2006 944 953 (Pubitemid 44454583)
28. J.A. Frank, N. Richert, C. Bash, L. Stone, P.A. Calabresi, and B. Lewis Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb + ve and NAb - ve patients Neurology 62 2004 719 725 (Pubitemid 38298946)
29. B. Turner, X. Lin, G. Calmon, N. Roberts, and L.D. Blumhardt Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years Mult Scler 9 2003 21 27 (Pubitemid 36253691)
30. J.T. Chen, D.L. Collins, H.L. Atkins, M.S. Freedman, A. Galal, and D.L. Arnold Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis Neurology 66 2006 1935 1937 (Pubitemid 44049833)
31. D.D. Mikol, F. Barkhof, P. Chang, P.K. Coyle, D.R. Jeffery, and S.R. Schwid Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol 7 2008 903 914
32. P.W. O'Connor, M. Filippi, B. Arnason, G. Comi, S. Cook, D. Goodin BEYOND Study Group 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Lancet Neurol 8 2009 889 897
33. V.M. Anderson, J.W. Bartlett, N.C. Fox, L. Fisniku, and D.H. Miller Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates J Neurol 254 2007 1588 1594 (Pubitemid 350159908)
34. P.S. Sorensen Neutralizing antibodies against interferon-beta Ther Adv Neurol Disord 1 2008 62 78
35. A.R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick Effect of anti-IFN beat antibodies on MRI lesions of MS patients in the BECOME study Neurology 73 2009 1485 1492